Augclav Mechanism of Action

Pharmacology: Augclav is a combination of amoxicillin, penicillin antibiotic with a broad spectrum of bactericidal activity and clavulanic acid, an irreversible β-lactamase inhibitor which produces stable nonactive complexes and protects amoxicillin from degradation.
Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus.
Augclav processes a broad spectrum of activity. It is active against amoxicillin-susceptible microorganisms as well as against resistant β-lactamase producing bacteria including: Gram-positive aerobes (S. pneumonia, S. pyogenes, S. viridans, S. bovis, S. aureus, S. epidermidis, Listeria spp., Enterococcus spp.); Gram-negative aerobes (H. influenzae, Moraxella catarrhalis, E. coli, Proteus spp., Klebsiella spp., N. gonorrhoeae, N. meningitidis, Pasteurella multocida); Anaerobes (Peptococcus spp., Peptostreptococcus, Clostridium spp., Bacteroides spp., Actinomyces israelii).
The basic pharmacokinetic properties of amoxicillin and clavulanic acid are similar. Both components of Augclav are well absorbed after oral administration. Food has no effect on the degree of absorption. Peak serum concentration is achieved approximately 1 hour of ingestion or 1-2.5 hour after dosing (Augclav 625 mg tablet). The biologic half-life of amoxicillin is 78 minutes and that of clavulanic acid is 60-70 minutes.
Both components diffuse readily into most body tissues and fluids (lung, middle ear effusions, pleural and peritoneal fluid, uterus, ovarium, etc.). Both amoxicillin and clavulanic acid are excreted in urine; amoxicillin mainly unchanged, clavulanic acid partially metabolised. Small amounts may be excreted in the feces and exhaled breath.
In patients with impaired renal function, excretion of the drug from the body is delayed and it accumulates in the blood proportionately to the degree of renal impairment.
625 mg tablet: Augclav 625 is not active against Pseudomonas spp. and majority of Enterobacter and Serratia species.